Novartis has tapped up an artificial-intelligence-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions. What caught the Swiss pharma’s eye ...

Relation and Novartis collaborate to advance treatments for atopic diseases using AI and immuno-dermatology expertise. Relation receives $55 million upfront, with potential milestones up to $1.7 ...

Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

A common over-the-counter medication could significantly reduce the risk of colorectal cancer coming back. In a Swedish study, a low dose of aspirin was shown to slash recurrence in half for patients ...

Proposed tariffs that are the highest in a century. Threatened annexations of other countries. Pulling out of the Paris agreements to fight climate change. Slashes to the funding of public health ...

Entertainment insurance firm Albert G. Ruben, a pioneer in Hollywood and the global entertainment sector that provides specialized services to major film studios, independent production companies, ...

Exercise is generally good for you, but a new high-quality clinical trial finds that it’s so good, it can even knock back colon cancer—and, in fact, rival some chemotherapy treatments. The finding ...

Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for ...

After you’ve gone through ovarian cancer treatment, your doctor will work with you to make sure you stay well. But sometimes the cancer returns. Doctors call this “recurrence.” To check for any ...